Drug Discovery

Vaximm and BCME link on oral cancer immunotherapy platform

OSR Company Vaximm has signed a non-binding term sheet with Swiss-based life sciences investor BCM Europe (BCME) for a potential exclusive worldwide licence for Vaximm’s oral cancer immunotherapy platform, VXM01.

Aspen closes $115m in Series C to advance Parkinson’s cell therapy

US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead autologous cell therapy candidate, ANPD001, for moderate-to-advanced Parkinson’s disease.

Alvotech and Advanz announce EC approval for Gobivaz biosimilar

Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across the European Economic Area (EEA).

EC authorises Roche’s Lunsumio SC for follicular lymphoma

Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) subcutaneous (SC) for adults with relapsed or refractory follicular lymphoma (R/R FL) after at least two systemic therapies.

Insmed receives EC approval for Brinsupri to treat NCFB

Insmed has received approval from the European Commission (EC) for Brinsupri (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and above with two or more exacerbations in the year preceding treatment.

Sofinnova closes €650m healthcare fund for early-stage ventures

Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed at supporting early-stage healthcare companies in the US and Europe, at €650m ($750m) above its initial target.

BostonGene and Kyoto University link on oesophageal cancer drug

BostonGene and Kyoto University have collaborated to advance precision drug development for oesophageal squamous cell carcinoma.

Novartis opens California site for RLT manufacturing

Novartis has opened a 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad in the US state of California, as part of its $23bn investment in the country’s infrastructure up to 2030.

SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases

SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases.